Compass Therapeutics, Inc.

CMPX Nasdaq SEC CIK 1738021
Follow Compass Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$27.2M −90.6% vs same quarter last year
EPS, diluted −$0.15 −87.5% vs same quarter last year
Operating cash flow −$16.3M −50.4% vs same quarter last year
Operating income −$28.8M −82.1% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
Q4 24 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$100M−$75M−$50M−$25M$0$25MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$66.5M
FY24$850K−$49.4M
FY23$0−$42.5M
FY22-−$39.2M
FY21-−$82.2M
FY20-−$29.5M
FY19-−$34.7M
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$49.2M
FY24−$44.9M
FY23−$40.6M
FY22−$34.3M
FY21−$21.2M
FY20−$26.9M
FY19−$32.2M
FY18-